Systemic Sclerosis (SSc) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)

Publication ⇒Nov-23  Delivery Time ⇒ 5-7 Business Days Report Code ⇒PBCHC215-8M-TR

License Type (Price in USD)

Systemic Sclerosis (SSc) – Report Overview

Pacific Business Consulting’s “Systemic Sclerosis (SSc) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)” report offers a comprehensive exploration of Systemic Sclerosis (SSc), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

Pacific Business Consulting anticipates strong growth in the global Systemic Sclerosis (SSc) market, covering the eight major pharmaceutical markets (U.S., U.K., Germany, France, Italy, Spain, Japan, and China), with a projected Compound Annual Growth Rate (CAGR) exceeding 10%. Sales are expected to surge from US$600 million in 2022 to US$2.0 Billion in 2030. This growth is driven by the increased adoption of Boehringer Ingelheim’s recently launched Ofev (nintedanib) and Roche/Genentech’s Actemra/RoActemra (tocilizumab) for treating SSc-associated Interstitial Lung Disease (ILD). Additionally, the market is poised for expansion with the anticipated approval and launch of six pipeline therapies.

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by progressive fibrosis affecting the skin, internal organs, and vascular function. The disease manifests heterogeneously, impacting various organ systems with varying severity. Common complications include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, ILD, pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. Currently, no systemic disease-modifying therapies exist that significantly alter the disease course, leading to a treatment paradigm focused on managing complications within individual organ systems.

Promising emerging treatment options are being explored for systemic sclerosis, particularly targeted therapies that modulate specific disease pathways. Drugs focusing on cytokines and immune cells, such as interleukin-17 (IL-17) inhibitors and CD19-targeted therapies, are under investigation.

These emerging treatments hold promise for improving systemic sclerosis management by addressing key mechanisms involved in disease progression. However, sales may face limitations due to erosion from generic nintedanib and biosimilars. Key market players contributing to the Systemic Sclerosis market include Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb Co., Chugai Pharmaceutical Co Ltd., Civi Biopharma Inc., Corbus Pharmaceuticals Inc., Eicos Sciences Inc., and F. Hoffmann-La Roche Ltd.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Systemic Sclerosis (SSc) market. It also delves into the analysis of present and prospective market competition within the Systemic Sclerosis (SSc) market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the Systemic Sclerosis (SSc) market across the 8MM (Eight Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Systemic Sclerosis (SSc) market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

  1. Executive Summary: Systemic Sclerosis (SSc)
    • Global Market Outlook: Systemic Sclerosis (SSc)
  2. Competitive Intelligence Analysis: Systemic Sclerosis (SSc)
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: Systemic Sclerosis (SSc)
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Disease Overview: Systemic Sclerosis (SSc)
    • Disease Etiology
    • Pathophysiology
    • Risk Factors
    • Treatment Algorithm
  7. Systemic Sclerosis (SSc): Key Marketed Products Profile – Major Approved Products
    • Product Profile
    • Regulatory Milestones
    • Safety and Efficacy
    • Clinical Development
  8. Systemic Sclerosis (SSc): Promising Pipeline Candidates – Major Products in Late Stage of Development
    • Product Description
    • Safety and Efficacy
    • Research and Development
  9. Regulatory Landscape
  10. Systemic Sclerosis (SSc): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  11. S. Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  12. K. Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  13. Germany Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  14. France Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  15. Italy Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  16. Spain Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  17. Japan Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  18. China Systemic Sclerosis (SSc) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
  4. Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com